Gregory L. Shiferman

CIK: 0002041689

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (35.7%)

Compensation grants

Other (G, F, J, C, D, …)9 (64.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

VYGR

Voyager Therapeutics, Inc.

Officer

SAGE

Sage Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

VYGR
Voyager Therapeutics, Inc.
Apr 1, 2026
Award(A)
Direct
50K shares-
VYGR
Voyager Therapeutics, Inc.
Jan 6, 2026
Award(A)
Stock Option (Right to Buy)
Direct
100K shares-
SAGE
Sage Therapeutics, Inc.
Jul 31, 2025
Disposition(D)
Direct
23.7K shares-
SAGE
Sage Therapeutics, Inc.
Jul 31, 2025
Tender Offer(U)
Direct
7.2K shares-
SAGE
Sage Therapeutics, Inc.
Jun 24, 2025
Tax Payment(F)
Direct
79 shares at avg. $9.22$728.38
SAGE
Sage Therapeutics, Inc.
Apr 10, 2025
Award(A)
Direct
525 shares-
SAGE
Sage Therapeutics, Inc.
Apr 10, 2025
Tax Payment(F)
Direct
176 shares at avg. $6.91$1K
SAGE
Sage Therapeutics, Inc.
Mar 24, 2025
Tax Payment(F)
Direct
79 shares at avg. $8.21$648.59
SAGE
Sage Therapeutics, Inc.
Feb 24, 2025
Tax Payment(F)
Direct
2.5K shares at avg. $7.49$19K
SAGE
Sage Therapeutics, Inc.
Feb 13, 2025
Tax Payment(F)
Direct
251 shares at avg. $7.18$2K
SAGE
Sage Therapeutics, Inc.
Feb 13, 2025
Tax Payment(F)
Direct
376 shares at avg. $7.18$3K
SAGE
Sage Therapeutics, Inc.
Jan 16, 2025
Award(A)
Direct
14K shares-
SAGE
Sage Therapeutics, Inc.
Dec 24, 2024
Tax Payment(F)
Direct
79 shares at avg. $5.48$432.92
SAGE
Sage Therapeutics, Inc.
Nov 1, 2024
Award(A)
Direct
5K shares-

		Type	Shares	Price		Ownership
Apr 1, 2026	VYGR Voyager Therapeutics, Inc.	Award(A)	50,000	-	$0	Direct
Jan 6, 2026	VYGR Voyager Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	100,000	-	-	Direct
Jul 31, 2025	SAGE Sage Therapeutics, Inc.	Disposition(D)	23,735	-	-	Direct
Jul 31, 2025	SAGE Sage Therapeutics, Inc.	Tender Offer(U)	7,215	-	-	Direct
Jun 24, 2025	SAGE Sage Therapeutics, Inc.	Tax Payment(F)	79	$9.22	$728	Direct
Apr 10, 2025	SAGE Sage Therapeutics, Inc.	Award(A)	525	-	-	Direct
Apr 10, 2025	SAGE Sage Therapeutics, Inc.	Tax Payment(F)	176	$6.91	$1,216	Direct
Mar 24, 2025	SAGE Sage Therapeutics, Inc.	Tax Payment(F)	79	$8.21	$649	Direct
Feb 24, 2025	SAGE Sage Therapeutics, Inc.	Tax Payment(F)	2,502	$7.49	$18,740	Direct
Feb 13, 2025	SAGE Sage Therapeutics, Inc.	Tax Payment(F)	251	$7.18	$1,802	Direct
Feb 13, 2025	SAGE Sage Therapeutics, Inc.	Tax Payment(F)	376	$7.18	$2,700	Direct
Jan 16, 2025	SAGE Sage Therapeutics, Inc.	Award(A)	14,000	-	$0	Direct
Dec 24, 2024	SAGE Sage Therapeutics, Inc.	Tax Payment(F)	79	$5.48	$433	Direct
Nov 1, 2024	SAGE Sage Therapeutics, Inc.	Award(A)	5,000	-	$0	Direct

1-14 of 14 transactions

About Shiferman Gregory L.

Shiferman Gregory L. (SEC CIK 0002041689) files insider reports with the SEC as SVP and General Counsel of Voyager Therapeutics, Inc. (VYGR) and Officer of Sage Therapeutics, Inc. (SAGE).

Signal8 holds 13 ownership filings by Shiferman Gregory L. (2 Form 3, 11 Form 4), filed between Nov 1, 2024 and Apr 3, 2026. Those filings report 14 transactions, from Nov 1, 2024 to Apr 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Shiferman Gregory L.'s filings is in LEXINGTON, MA.

Recent filings by Shiferman Gregory L.

Apr 1, 2026: Grant or award of VYGR shares (Form 4, code A).
Jan 6, 2026: Grant or award of VYGR derivative securities (Form 4, code A).
Jul 31, 2025: Disposition to issuer transaction of SAGE shares (Form 4, code D).
Jul 31, 2025: Tender of shares transaction of SAGE shares (Form 4, code U).
Jun 24, 2025: Tax withholding of SAGE shares (Form 4, code F).

Other insiders filing for Voyager Therapeutics, Inc. (VYGR)

SCANGOS GEORGE A, Director
MACKEY CATHERINE J, Director
Hyman Steven, Director
Vitale Nancy, Director
Higgins Michael J, Director
Onyia Jude, Director

How to read Form 4 transaction codes